This compound is a quinazoline-based derivative identified as an impurity of the active pharmaceutical ingredient afatinib. It is characterized by a dichloroaniline moiety and an oxolan-3-yloxy substituent, with stereochemistry specified at one chiral center.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 2223677-63-0
(S,E)-N-(4-((4-CHLORO-3-FLUOROPHENYL)AMINO)-7-((TETRAHYDROFURAN-3-YL)OXY)QUINAZOLIN-6-YL)-4-(DIMETHYLAMINO)BUT-2-ENAMIDE
active pharmaceutical ingredient
(S,E)-N-(4-((3,4-Difluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide (Afatinib Impurity)
Afatinib impurity reference standard
Afatinib Impurity 18
Pharmaceutical impurity reference standard
Calcium;(3R,5R)-7-[2-(4-fluorophenyl)-3-(2,3,4,5,6-pentadeuteriophenyl)-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
active pharmaceutical ingredient
(endo,Anti)-(1)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-isopropyl-8-methyl-8-azoniabicyclo(3.2.1)octane bromide
active pharmaceutical ingredient
BROMOCRIPTINE MESYLATE
Active pharmaceutical ingredient
Val-Cit-PAB-Exatecan
Antibody-drug conjugate payload-linker
(E)-N-[4-(3,4-dichloroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
GMLBQFFEIVQHIS-CWDCEQMOSA-N
CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)Cl)Cl)O[C@H]4CCOC4